Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 4/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCC5 | O15440 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verlukast SCHEMBL37246 | 1.00 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Mk-571 SCHEMBL30509651 | 1.00 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Mk-571 SCHEMBL9231584 | 1.00 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Verlukast SCHEMBL37247 | 1.00 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Mk-571 SCHEMBL156452 | 0.99 | CYSLTR1 (0.98) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Verlukast SCHEMBL156454 | 0.99 | CYSLTR1 (0.98) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Dimethylcarbate SCHEMBL9327878 | 0.95 | CYSLTR1 (0.90) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| SCHEMBL17833480 | 0.94 | CYSLTR1 (0.89) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| SCHEMBL9267947 | 0.93 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| SCHEMBL9265732 | 0.93 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4851409-A | LEUKOTRIENE ANTAGONIST, ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY, CYTOPROTECTIVE | MERCK FROSST CANADA INC. (CA) | 1989-07-25 | — | — | US | claimed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | disclosed |
| US-12421281-B2 | Cyclosporine compositions and methods of use | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-09-23 | — | — | US | disclosed |
| US-20250179121-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-06-05 | — | — | US | disclosed |
| WO-2025085674-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ULCERATIVE COLITIS | BACAINN THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12252556-B2 | Cyclosporine compositions and methods of use | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-03-18 | — | — | US | disclosed |
| EP-4438618-A2 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | Bacainn Biotherapeutics, Ltd. (KY) | 2024-10-02 | — | — | EP | disclosed |
| US-20240277798-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2024-08-22 | — | — | US | disclosed |
| EP-3840769-B1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS LTD (KY) | 2024-07-24 | — | — | EP | disclosed |
| US-20240207212-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | UNIVERSITY OF MASSACHUSETTS | 2024-06-27 | — | — | US | disclosed |
| US-20050165041-A1 | Combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1517706-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA Pharma AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003094968-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| US-5428171-A | Leukotrienes antagonist; antiasthmatic, antiallergic, anti-inflammatory and cytoprotective agent | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| EP-0641569-A1 | ANTIPRURITIC | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| US-5136034-A | Reacting an arylaldehyde with mercaptan and thioacyl in presence of acid catalysts; then reacting with electrophile | MERCK FROSST CANADA, INC. (CA) | 1992-08-04 | — | — | US | disclosed |
| US-4851409-A | LEUKOTRIENE ANTAGONIST, ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY, CYTOPROTECTIVE | MERCK FROSST CANADA INC. (CA) | 1989-07-25 | — | — | US | disclosed |
| EP-0233763-A2 | 2-Substituted quinoline dioic acids | MERCK FROSST CANADA INC. (CA) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252556-B2 | Cyclosporine compositions and methods of use | FPR2, FPR1, FPR3 | CYSLTR1 49/4885ABCC1 5/4885ABCC2 7/4885 |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | ABCC1, SLC47A2, ABCB1 | CYSLTR1 585/4885ABCC1 1/4885ABCC2 4/4885 |
| US-20240207212-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION | ABCC3, ABCC1, ABCE1 | CYSLTR1 190/4885ABCC1 2/4885ABCC2 5/4885 |
| US-12421281-B2 | Cyclosporine compositions and methods of use | FPR2, FPR1, FPR3 | CYSLTR1 104/4885ABCC1 12/4885ABCC2 4/4885 |
| US-20240277798-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | FPR1, FPR3, FPR2 | CYSLTR1 17/4885ABCC1 27/4885ABCC2 1383/4885 |
| US-20250179121-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | FPR2, FPR1, FPR3 | CYSLTR1 49/4885ABCC1 5/4885ABCC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.